The aim of the study was to demonstrate differences in the gene expression of signalling pathways between healthy dogs and dogs with chronic mitral valve disease in different heart failure groups. Blood samples were collected from 49 dogs of various breeds between 1.4 and 15.2 years of age. Isolated RNA samples were analysed for quality and integrity and the gene expression profile was determined. The study demonstrated that nucleated cells from peripheral blood can be used to assess the status of heart failure in dogs. Furthermore, significant differences in the expression of the genes were noticed between healthy dogs and dogs with clinical signs of chronic mitral valve disease. This is a preliminary non-invasive study showing the feasibility of genetic testing from peripheral blood nucleated cells, which at the same time has made it possible to set the future directions of genetic studies in clinical cases of canine chronic mitral valve disease.
Introduction
Chronic degenerative mitral valve disease (MVD), called also myxomatous mitral valve disease or endocardiosis, is the most common acquired heart disease in dogs. It accounts for over 70% of heart disease in veterinary practice and most frequently occurs in older dogs of small breeds, especially the dachshund, cavalier King Charles spaniel, Pekingese, Chihuahua, toy and miniature poodles, and Maltese (1, 12, 19, 20) . It is believed that the disease is inherited in breeds such as the cavalier King Charles spaniel and dachshund (17, 21) and there may be a similar genetic predisposition to the disease in other dog breeds. For such reasons there is an ongoing interest in genetic research, which might be able to elucidate which are the genes responsible for the disease. There are many factors making genetic studies difficult, the most important of which are cost barriers and a lack of accessible research material (biopsy) from live animals. Until these barriers can be overcome, attempts are being made to use easily accessible blood cells for genomic studies. Such studies do not reveal which are the genes responsible for the particular disease, but do allow the assessment of gene expression, as they enable the analysis of the whole genome. Gene expression may play a role in the development and progression of heart diseases and the studies can be used to further our knowledge of canine MVD by showing differences between healthy and diseased dogs, as well as between the different stages of MVD (6, 18) . They might provide not only information about the disease process, but also possible new biomarkers to be used in cardiovascular diagnostics and therapy assessment.
The natural progression of MVD is connected with the appearance of clinical signs such as exercise intolerance, cough, dyspnea, tachypnea, ascites, syncope, and/or collapse. According to the ACVIM Consensus Statement, it is presently categorised from Stage A to Stage D. Stage A refers to patients at high risk of developing MVD, Stage B encompasses patients with structural changes but no clinical signs of heart failure, Stage C refers to patients with previous or present signs of heart failure, and Stage D applies to patients with refractory heart failure (1).
Transcriptome profiling tissue studies in dogs with MVD have shown an increase in the transcription of several signalling pathways including cell signalling, inflammation, extracellular matrix, cell defence, immune function, and metabolism (18) . Studies on affected tissues have shown up-regulation of MMP-1 and MMP-9 as well as collagen III (25) , serotonin receptor 2B (18) , MMP-1, MMP-14, and tissue inhibitors of metalloproteinases (TIMPs) such as TIMP-2, TIMP-3, and TIMP-4 (2, 3). Studies of tissue from affected hearts have also shown down-regulation of gene expression in the course of mitral valve disease, namely down-regulation of the microfibrillar, glycoprotein, and noncollagen extracellular matrix genes, TGF-ßR2, TGF-ß R3, and connective tissue growth factor (25) ; several MMPs, including MMP-2 (2), MMP-1, and MMP-13 (4); and TGF-ß3, TßR-II, αSMA, and MMP-3 (16) .
The goal of this preliminary study was to present differences in gene expression of signalling pathways between healthy dogs and dogs with MVD as well as between dogs in the different heart failure groups.
Material and Methods
Blood samples were collected from 49 male and female dogs of various breeds, ranging from 1.4 to 15.2 years of age. The samples were divided according to the ACVIM classification scheme: 13 Stage B, 13 Stage C, 12 Stage B, and 11 healthy/Stage A. The study population characteristics are shown in Table 1 .
Blood samples were collected from the cephalic or jugular veins into an Rneasy Protect Animal Blood Tube (Qiagen, USA). The total RNA from nuclei of peripheral blood cells, mainly leukocytes, was isolated using a Rneasy Protect Animal Blood Kit (Qiagen, USA). Isolated RNA was dissolved in REB buffer from the test kit. The RNA quantity was measured spectrophotometrically using a NanoDrop (NanoDrop Technologies, USA). The analysis of final RNA quality and integrity was performed with a BioAnalyzer (Agilent, USA). The analysis of the gene-expression profile was performed using a Canine (V2) Gene Expression Microarray, 4x44K (Agilent Technologies, USA). Each slide contained four microarrays representing about 45 000 canine predicted mRNAs. The experiments were performed using a common reference design, where the common reference was a pool of equal amounts of RNA from 10 healthy dogs. On each two-colour microarray, 100 ng of total RNA from the pool and 100 ng of total RNA from one of 49 patients were hybridised. Sample labelling, amplification, and microarray hybridisation were performed with the appropriate kits supplied by the manufacturer (Agilent Technologies, USA), according to the manufacturer's protocols. Analysis of hybridisation intensity was performed using an Agilent DNA microarray scanner.
Statistical analysis was performed using Gene Spring Software (Agilent, USA). A Student's t-test was used to find genes with altered expression between research groups (adjusted P-value < 0.05; FDR corrected). The differentially expressed transcripts were then analysed using the Panther Classification System programme, which organises the transcripts according to their function including: molecular function, biological processes, cellular components, protein classes, and signalling pathways.
Results
Since there were significant differences in the expression of genes between healthy/Stage A dogs and dogs with Stage C heart failure signs, and between dogs in the Stage B and C groups, further analysis was performed with respect to dogs without clinical signs of MVD (healthy/Stage A or Stage B) and dogs with clinical signs of disease (Stage C). The number of differen-tially regulated genes is shown in Table 2 . (1) Rottweiler (1) 1.4-10.5 years 5 6 There were 1127 common differentially expressed genes between healthy/Stage A dogs or Stage B dogs and dogs with Stage C clinical signs; however, only 646 genes have been previously described and named. Therefore, further analysis was possible only for these 646 differentially regulated genes. Table 3 presents the ontology. Of the genes involved in molecular functions that were differently regulated between the asymptomatic and symptomatic dogs, the most prominent were involved in binding and catalytic activity, followed by transcription regulator and structural molecule activity. Of the biological processes in which differentially expressed genes were involved, the largest number were involved in metabolic and cellular processes, followed by cell communication, cell cycle, transport, and develop-mental processes. Differentially regulated genes that were involved in different pathways were mostly represented in the gonadotropin releasing hormone receptor pathway and the inflammation mediated by chemokine and cytokine signalling pathway. 
Discussion
Gene expression studies can identify distinctive subgroups of genes associated with a specific disease, stage of disease, and/or disease process. A recent study showed that matrix metalloproteinases 2 and 9 (MMPs), key enzymes responsible for myocardial remodelling during heart disease, are up-regulated in the failing myocardium but not in skeletal muscles in pigs with tachycardia-induced cardiomyopathy (8) . MMPs are enzymes found throughout the body that are responsible for remodelling of tissues. The latter study emphasises a local process of particular MMPs within the heart and may be used to plan further studies on the pathological processes within the myocardium. Few studies have been performed on the expression of peripheral blood cells with respect to the changes seen in chronic MVD. Moon et al. (13) and Na et al. (15) showed an increased expression of the Na Microarrays are a tool used for creating new hypotheses, which in this study are mainly related to the appearance of clinical signs of MVD. The presented study showed significant differences in gene expression between healthy dogs, whether they were disease free, belonging to Stage A or Stage B, or symptomatic dogs belonging to the Stage C mitral valve disease group. Thus, it would appear that the differentially expressed genes may be responsible for the occurrence of clinical signs of MVD or compensatory processes for the consequences of MVD within the body.
Molecular function describes the activity of each gene product. One gene product might be responsible for several different functions, while several different genes might be responsible for the production of substances that have similar functions. Of the differentially expressed gene products, the largest numbers were involved in binding and catalytic activity. Binding activity refers to the selective and non-covalent interaction between the gene product (i.e. a protein) and a specific substance (i.e. other proteins, enzymes, or molecules). Genetic studies in cardiology have shown an increase in syntax-binding protein and syntaxin 2, which are possibly involved in the secretion of von Willebrand factor (VWF). Increased concentrations of VWF are associated with a higher cardiovascular disease risk (24) . The studies performed on rats have shown an increase in BNP GATA4 binding activity in the heart that was brought about by a pressure overload in vivo via the endothelin-1 signalling molecule (7). Catalytic activity within gene ontology refers to the function of enzymes on biochemical reactions within an organism. Without catalysis they would often not occur at a significant level. Genetic studies are often performed to show inhibition or stimulation of catalytic activity by a particular chemical substance. The study on rats showed that by inhibiting the catalytic activity of some isoforms of histone deacetylase enzymes it may be possible to block pathological myocardial remodelling in heart failure. Histone deacetylases are enzymes responsible for removing acetyl groups from histones (proteins responsible for tightly packing DNA into nucleosomes) and the class I isoform may be involved in pathological cardiac remodelling (10) . Our study demonstrates a significant number of changes in the expression of the genes involved in molecular function across the studied groups of dogs, especially in binding and catalytic activity (Table 3) . This large number of differences warrants further investigation to establish more precisely the changes seen in gene expression within this functional group.
Biological processes are documented events or molecular functions occurring in a series. The largest number of differentially regulated genes was noted in metabolic and cellular processes. Studies have looked into them with respect to the cardiovascular system in humans and rats. It has been shown that improper substrate metabolism can contribute to systolic myocardial dysfunction, consequently leading to heart failure. Studies in canine models of tachycardiainduced heart failure have shown a down-regulation of fatty acid oxidation enzymes, including amongst others expression of MCAD and CPT-1 activity, and an upregulation of carbohydrate oxidation during advanced stages of heart failure (22) .
Cell specific RNA-binding proteins play a role in normal heart development and have been implicated in the pathology of myotonic dystrophy in humans, a multisystemic inherited disease, which causes heart conduction abnormalities (14) . In this study genes coding for proteins from the nucleic acid binding proteins group were the most differentially expressed between the two studied groups of dogs.
Signalling pathways are a complex set of interactions between a group of genes essential for the proper function of a cell, group of cells, tissues, and finally the organism. These groups of genes are dependent on each individual gene. One mutated gene that is consequently dysfunctional can lead to a cascade of changes in its pathway. In our study, one of the pathways that showed the greatest differences between transcripts of healthy and affected dogs was the gonadotropin releasing hormone receptor (GnRHR) pathway. GnRHR is a receptor found on the surface of pituitary gonadotropin-releasing cells, lymphocytes, mammary gland cells, ovaries, and the prostate and binds gonadotropin-releasing hormone (GnRH). To date, no studies have shown a direct relationship between GnRHR and heart disease; however, they do suggest that GnRH agonists, used to treat prostate cancer, may increase the risk of heart disease (23). Another example is the gene coding for the androgen receptor. For years, it has been believed that oestrogens play a cardioprotective role in women before menopause. Recent genomic studies have disproven this hypothesis, showing a tendency for lower testosterone levels in men with cardiovascular disease and that testosterone supplementation improves myocardial ischaemia (11) . Our studies also show a tendency for heart disease to appear earlier or more frequently in male dogs than in females (5) .
These are just a few examples of the present trend of studies into explaining specific roles in the physiology and pathology of gene transcription and its role in heart disease. Each study helps to understand the underlying abnormality of each heart disease, including mitral valve disease in dogs. To date, genetic profiling of peripheral nuclear cells has not been performed in dogs with naturally occurring mitral valve disease.
This study is a first step towards setting further directions for genetic studies on clinical cases of canine mitral valve disease. While the studies reported by other authors and referred to in the discussion section were performed on tissue samples, this study shows that genetic testing from peripheral blood nucleated cells is a feasible study method in the canine model. The next step in our project is to look into the specific transcriptional changes in dogs with different stages of mitral valve disease. The list of differentially regulated genes for further studies could include new potential biomarkers of heart disease in dogs. Therefore, we consider the results of our investigation a promising area of further research. It is important to emphasise that the results of this study are a reflection of the systemic response to heart disease despite the fact that the study limitations include relatively small and diverse groups of dogs with respect to breed and age.
